Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
1.2K Following 147.2K Followers
80% of heart disease and stroke is preventable, per the American Heart Association. Yet it’s still the world’s leading cause of death.
Obesity raises the risk of type 2 diabetes and cardiovascular disease. A post-hoc analysis showed our oral obesity medicine was associated with reductions in the predicted risk of both conditions, with reductions seen across all doses. Read more:
Show more
What we see on the surface of the skin doesn't always tell the full story. New data at EADV showed meaningful and rapid improvements in skin clearance, itch and pain in moderate-to-severe hand and foot AD.
Show more
The heart deserves as much attention as blood sugar in type 2 diabetes. In our largest, longest study of an oral GLP-1, presented at #EASD2026#, the trial met its cardiovascular safety endpoint vs. insulin glargine. Read more:
Show more
Presented at #EASD2026#, our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results in adults with obesity and type 2 diabetes: substantial weight loss and A1C reduction. Read more:
Show more
Treating obesity & type 2 diabetes together can be challenging, but new research presented at #EASD2026# showed our investigational treatment, when taken at the highest dose, helped more than half of participants no longer have obesity, and nearly 40% reach a normal A1C.
Show more
New clinical research, published in @nejm, showed our investigational triple agonist, taken at the highest dose, helped patients lose an average of 70.3 pounds.
New information for HCPs: A new indirect treatment comparison presented at the #EASD2026# annual meeting compared the highest dose of our dual GIP/GLP-1 obesity medicine with the highest dose of another obesity medicine. Read more:
Show more
New evidence for HCPs: A new indirect treatment comparison, shared today at #EASD2026#, evaluated the highest dose of our oral GLP-1 alongside a higher dose of another oral medicine for type 2 diabetes:
Show more
Our goal: improve access to quality healthcare for 30M people living in resource-limited settings annually by 2030—and we’ve met it five years early. Today we launch Lilly Change the Course Commitment, aiming to bridge the gap in diabetes and obesity care in those areas.
Show more
In Milan, Italy, we're opening House of Lilly during #EASD2026#. It brings art and science together to share our history, the inspiration behind our innovation and the science behind what comes next as we work to change the course of cardiometabolic health.
#WeAreLilly#
Show more
We’re breaking ground in Houston, TX — the latest manufacturing site as part of our $50+ billion investment in domestic production. Not only will this new facility create hundreds of jobs, but it will help us get our medicines to people faster.
#WeAreLilly#
Show more
What keeps us awake, alert and engaged each day?
See how orexin, a signal deep in the brain, may help influence everyday life:
#WorldNarcolepsyDay#
Obesity and type 2 diabetes rarely occur alone. That's why it's important to have treatment options that address different patient's needs. This is the thinking behind our work at the upcoming #EASD2026# conference in Milan, Italy. Read more about our approach:
Show more
Today, the FDA approved Lilly's new oral treatment for people with ESR1-mutated #BreastCancer#, which targets two key drivers of ER+ breast cancer. Learn more:
Show more
Millions of people live with diabetes and obesity, and the science keeps moving forward. This month, researchers and clinicians will gather in Milan for #EASD2026#. We'll be there, sharing new findings as we work together to advance cardiometabolic health:
Show more
New one-year data showed durable improvements in psoriasis, psoriatic arthritis and obesity:
When you live with type 2 diabetes, the conversation is usually about blood sugar. It should also be about your heart❤.
Read more:
Heart disease is the leading cause of death for people living with type 2 diabetes. Today the FDA approved a new use for one of our type 2 diabetes medicines, lowering the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk for these events. Read more:
Show more
Lilly’s injectable weight management medicine was linked to lower healthcare costs over time compared to those not on treatment. Read more from this new study:
Show more
